Nurogab 75 Tablet SR contains Pregabalin 75 mg, an anticonvulsant and neuropathic pain agent. It is primarily indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury. Additionally, it is used as adjunctive therapy for partial-onset seizures in adults. Pregabalin acts by binding to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, thereby reducing the release of excitatory neurotransmitters and modulating neuronal excitability. Nurogab 75 Tablet SR is formulated as a sustained-release tablet to provide prolonged therapeutic effects and improve patient compliance by reducing dosing frequency. Common adverse effects may include dizziness, somnolence, dry mouth, and peripheral edema; patients should be monitored for signs of hypersensitivity and mood changes. Dose adjustments may be necessary in patients with renal impairment. It is contraindicated in individuals with known hypersensitivity to pregabalin or any of the tablet excipients. Caution is advised when prescribing to patients with a history of substance abuse or depression. Nurogab 75 Tablet SR should be used under medical supervision, with careful titration to minimize side effects and optimize clinical outcomes.